The Biotechnology Innovation Organization backed an FDA Fit-for-Purpose Rare Disease Framework initiative at a public meeting, arguing it could create more consistent, patient-centered guidance for rare disease development. BIO’s position highlights the need for earlier alignment, clarity in regulatory decision-making, and structured uncertainty handling. Rare disease developers often face small populations and limited natural history data, making standard trial designs difficult to execute. BIO’s advocacy suggests the industry is pushing for mechanisms that can reduce friction without lowering evidence expectations. The initiative is positioned as a preemptive guideline effort, with written feedback requested through mid-December.